SEC Form 4 · accession 0000899243-17-028854
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel W. Hunt
Officer — SVP, Chief Business Officer
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.60 | Dec 13, 2017 | A | 200,000 | A | — | Dec 13, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to twenty-five percent (25%) of the shares subject to the option on November 27, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.